Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Follow-up study of atezolizumab in urothelial cancer after platinum failure
jRCT2080223372Phase 3Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Nov 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of atezolizumab in transitional cell carcinoma (TCC), sponsored by Chugai Pharmaceutical Co., Ltd. Started Nov 2016; status: completed.
02
Drugs
atezolizumab
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on jRCT2080223372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223372.